Sei Investments CO Bei Gene, Ltd. Transaction History
Sei Investments CO
- $75.3 Billion
- Q4 2024
A detailed history of Sei Investments CO transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Sei Investments CO holds 5,193 shares of BGNE stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,193
Previous 12,815
59.48%
Holding current value
$1.18 Million
Previous $2.88 Million
66.67%
% of portfolio
0.0%
Previous 0.0%
Shares
27 transactions
Others Institutions Holding BGNE
# of Institutions
251Shares Held
45.6MCall Options Held
322KPut Options Held
144K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.4 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.46 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.17 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA5.1MShares$1.16 Billion0.74% of portfolio
-
Baillie Gifford & CO3.67MShares$832 Million0.54% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...